• Iron Stress Reprograms Enterocyte Metabolism

  2026-08-19

  Navazesh and Ji show that both iron deficiency and iron excess reprogram enterocyte metabolism, but through distinct molecular and inflammatory patterns. Their IPEC-J2 model integrates time-resolved transcriptional analysis, LPS stimulation, untargeted metabolomics, and iron repletion to clarify how intestinal epithelial cells respond to iron stress.

• ECL Western Blotting Substrate: Workflow Guide

  2026-08-19

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection on immunoblots. It is intended for HRP chemiluminescent workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection.

• AM 281 Workflows for CB1 Signaling Research

  2026-08-18

  AM 281 combines nanomolar CB1 affinity with strong CB2 selectivity for mechanistic studies of cannabinoid signaling, glutamate homeostasis, and cognition. This workflow-focused guide translates the CB1-CREB-GLT-1 findings in traumatic brain injury into practical assay design, controls, and troubleshooting decisions.

• LY2603618: Practical Chk1 Inhibition Workflows

  2026-08-18

  Learn how LY2603618 (SKU A8638) can improve the interpretation and handling of Chk1 inhibition experiments involving viability, proliferation, cell-cycle, and DNA-damage endpoints. This scenario-based guide connects product specifications with practical assay design and recent biomarker evidence.

• Balsalazide disodium: IBD Research Workflows

  2026-08-17

  Balsalazide disodium supports two complementary research paths: azoreductase-aware inflammation assays and radiolabeled colon-targeting studies. This practical guide connects stock preparation, chloramine-T radioiodination, inflammatory bowel disease models, assay controls, and troubleshooting.

• Fosinopril Sodium: From ACE Mechanism to Translation

  2026-08-16

  Fosinopril sodium offers translational researchers more than a conventional ACE inhibition tool. Its phosphinic acid zinc-binding pharmacophore, prodrug activation, and renal–hepatic disposition create a framework for connecting biochemical potency with blood pressure reduction, renal hemodynamics modulation, and cardiovascular remodeling in research models.

• Machine-Learning Discovery of Senolytics

  2026-08-15

  The reference study shows that cost-effective machine learning trained on published, heterogeneous screening data can prioritize senolytic compounds for experimental validation. Its identification of ginkgetin, periplocin, and oleandrin illustrates a practical route from sparse literature data to candidate discovery while highlighting the need for cell-type and senescence-modality controls.

• AI-10-49 and the CBFβ-SMMHC AML Bottleneck

  2026-08-15

  AI-10-49 offers a mechanism-led way to study inv(16) acute myeloid leukemia by disrupting the oncogenic CBFβ-SMMHC–RUNX1 interaction. This thought-leadership guide connects target engagement, chromatin restoration, MYCN/eIF4G1-dependent survival, and translational assay design while clarifying the limits of preclinical interpretation.

• Triazole ALDH2 Activators in Myocardial Ischemia

  2026-08-14

  The 2025 ACS Medicinal Chemistry Letters study reports triazole-based aldehyde dehydrogenase 2 activators designed with molecular simulation, led by compound Z17. Z17 showed unusually strong ALDH2 activation and improved cardiac function and biochemical injury markers in a mouse ischemia–reperfusion model, while also addressing solubility limitations associated with earlier activators.

• Zosuquidar (LY335979): P-gp MDR Reversal

  2026-08-14

  Zosuquidar, also called LY335979, is a selective P-glycoprotein modulator studied for reversing transporter-driven multidrug resistance in cancer models. Product information reports restored sensitivity to several chemotherapeutics at 0.1 μM in P-gp-overexpressing cells, while clinical studies show that pharmacodynamic inhibition does not guarantee improved patient outcomes.

• RITA and Better In Vitro Cancer Drug Evaluation

  2026-08-13

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent outcomes of anticancer treatment. This framework helps researchers design more interpretable cancer biology experiments, including studies that later compare in vitro responses with apoptosis assays or tumor xenograft models.

• Resveratrol: Designing Causal SIRT1 Assays

  2026-08-13

  Resveratrol is widely used as a SIRT1 activator, but its neuroprotective value is best tested through causal, pathway-resolved assays. This article translates recent N2a-cell findings into a rigorous framework for separating mitochondrial biogenesis, oxidative stress modulation, and apoptosis outcomes.

• RG108 and Oct4 Reprogramming in the Mouse Brain

  2026-08-12

  The Asadi et al. study compared RG108, BIX-01294, Bay K8644, and valproic acid during Oct4-driven reprogramming in the mouse brain. RG108 did not significantly improve pluripotency or neural stem-cell marker expression under the tested conditions, whereas valproic acid produced the strongest response, particularly when administered before Oct4 induction.

• Intestinal Stretch, Obesity, and Weight-Loss Recovery

  2026-08-12

  The reference study shows that intestinal stretch is an acute regulator of feeding and oral glucose tolerance that operates independently of classical GLP-1 signaling. Obesity weakens this gut–brain response, whereas both dietary weight loss and vertical sleeve gastrectomy restore stretch-induced satiety and enhance neuronal activation in the nucleus of the solitary tract.

• FMT Reduces Neuronal Death After Ischemic Stroke

  2026-08-11

  This rat study links fecal microbiota transplantation with improved neurological outcomes after middle cerebral artery occlusion, reduced infarct volume, and suppression of neuronal apoptosis, necroptosis, and inflammatory microglial activation. Its main contribution is an integrated analysis of several injury pathways, while its translational value remains limited by the animal model and the absence of direct microbiome-mechanism experiments.

460 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page